Skip to main content
Premium Trial:

Request an Annual Quote

1999 Ends on Positive Note for Biotechnology

Premium

S

AN FRANCISCO--1999 ended on a high note for the biotech industry as interest in sector stocks was renewed and a number of companies completed successful IPOs during the fourth quarter, according to private merchant bank Burrill. Unlike previous quarters when large and mid-sized biotech companies performed better than small ones, even smaller firms fared better as a whole, increasing 72 percent. Burrill credited renewed investor interest in genomics companies such as Abgenix, Celera Genomics, Human Genome Sciences, Incyte Pharmaceuticals, and Millennium Pharmaceuticals, whose stock prices more than doubled during the quarter.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.